Figure 1.
Association between pCR and survival.
DFS in pathologic non-responders was significantly (p = 0.01) shorter than that for responders, while OS was not significantly different (p = 0.12).
Table 1.
Clinical and pathological response in 102 primary breast cancers.
Figure 2.
Immunohistochemical staining of CD133 or ALDH1.
(A), Immunohistochemical determination of CD133 expression. The CD133 antibody stained intensely at the membrane and in the cytoplasm of cancer cells. Scores were applied as follows: 0, negative staining in all cells; 1+, weakly positive or focally positive staining in <10% of cells; 2+, moderately positive-staining in 10%-50% of cells; and score 3+, strongly positive-staining, involving 50% or more of the cells. (B), Immunohistochemical determination of ALDH1 expression. The ALDH1 antibody stained intensely at the membrane and in the cytoplasm of cancer cells. Scores were applied as follows: 0, negative staining in all cells; 1+, weakly positive or focally positive staining in <10% of cells; 2+, moderately positive-staining in 10%-50% of cells; and score 3+, strongly positive-staining, involving 50% or more of the cells.
Table 2.
Correlations between CD133 or ALDH1 expression and clinicopathological parameters in CNB of 102 primary breast cancers.
Table 3.
Univariate and multivariate analysis with pathological complete response in 102 breast cancers.
Table 4.
Univariate and multivariate analysis with respect to disease free survival in primary breast cancers.
Figure 3.
Association between CD133 expression and survival.
In CNB specimens before NAC, DFS and OS in patients with CD133-positive tumors were significantly shorter than those in patients with CD133-negative tumors. In resected tumors after NAC, DFS for patients with CD133-positive tumors were significantly shorter than for patients with CD133-negative tumors, while OS was not significantly different. Since 20 of the 102 breast tumors were of pathological grade 3 before NAC, CD133 expression was examined in only 82 tumors after NAC.
Table 5.
CD133 Status between pre-NAC CNB specimens and post-NAC resected tumors.
Figure 4.
Association between CD133 expression and survival before and after NAC.
DFS in patients CD133-positive tumors after NAC was significantly shorter than that for patients with CD133-neagtive tumors, while OS was not significant.